| Cell line name |
CPT-K5 |
|---|
| Synonyms |
CPT-K-5; CPTK5; RPMI 8402/CPTK5 |
|---|
| Accession |
CVCL_2878 |
|---|
| Resource Identification Initiative |
To cite this cell line use: CPT-K5 (RRID:CVCL_2878) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; CPT-11).
Omics: Array-based CGH.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: T-cell; CL=CL_0000084. |
|---|
| Sequence variations |
- Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=29496689).
- Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11986; TOP1; Simple; p.Asp533Gly (c.1598A>G); ClinVar=VCV000016773; Zygosity=Unspecified (PubMed=1849260).
- Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Childhood T acute lymphoblastic leukemia (NCIt: C7953)
Precursor T-cell acute lymphoblastic leukemia (ORDO: Orphanet_99861) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1667 (RPMI-8402) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
16Y |
|---|
| Category |
Cancer cell line |
|---|
| STR profile |
Source(s): JCRB; PubMed=29496689
Markers:| Amelogenin | X |
| CSF1PO | 9,10,11,12 |
| D2S1338 | 23,24,26,27 |
| D3S1358 | 14,15,16 |
| D5S818 | 11,12,13 |
| D7S820 | 9,12,14 |
| D8S1179 | 13,14 |
| D13S317 | 10,12 |
| D16S539 | 10,14 |
| D18S51 | 14,17,18 |
| D19S433 | 14,15 |
| D21S11 | 28,30,33.2,34.2 |
| FGA | 21,22,24 |
| TH01 | 6,7 |
| TPOX | 8 |
| vWA | 17,18,20,22 |
Run an STR similarity search on this cell line |
|---|
| Publications | PubMed=3039492; DOI=10.1073/pnas.84.16.5565
Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K.
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
Proc. Natl. Acad. Sci. U.S.A. 84:5565-5569(1987) PubMed=1849260; DOI=10.1093/nar/19.1.69
Tamura H.-o., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., Keene J.D., Okada K., Kjeldsen E., Nishikawa K., Andoh T.
Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.
Nucleic Acids Res. 19:69-75(1991) PubMed=14679002
Li T.-K., Houghton P.J., Desai S.D., Daroui P., Liu A.A., Hars E.S., Ruchelman A.L., LaVoie E.J., Liu L.F.
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Cancer Res. 63:8400-8407(2003) PubMed=29496689; DOI=10.21873/cgp.20068
Kjeldsen E., Nielsen C.J.F., Roy A., Tesauro C., Jakobsen A.-K., Stougaard M., Knudsen B.R.
Characterization of camptothecin-induced genomic changes in the camptothecin-resistant T-ALL-derived cell line CPT-K5.
Cancer Genomics Proteomics 15:91-114(2018) |
|---|
| Cross-references |
|---|
| Cell line collections (Providers) |
JCRB; JCRB1067
|
|---|
| Cell line databases/resources |
cancercelllines; CVCL_2878
|
|---|
| Biological sample resources |
BioSample; SAMN03472497
|
|---|
| Encyclopedic resources |
Wikidata; Q54814409
|
|---|
| Entry history |
|---|
| Entry creation | 04-Apr-2012 |
|---|
| Last entry update | 05-Oct-2023 |
|---|
| Version number | 22 |
|---|